{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:24:26Z","timestamp":1777893866226,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CHU Saint-\u00c9tienne"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12325-025-03304-6","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T11:01:17Z","timestamp":1753700477000},"page":"4659-4680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Effectiveness and Safety of Infliximab Biosimilar CT-P13 for Rheumatic Diseases: A National Observational Cohort Study (ReFLECT)"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct02925338","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1177-9497","authenticated-orcid":false,"given":"Hubert","family":"Marotte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8890-9099","authenticated-orcid":false,"given":"Alain","family":"Cantagrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9175-8620","authenticated-orcid":false,"given":"Fabienne","family":"Coury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6976-643X","authenticated-orcid":false,"given":"Thierry","family":"Schaeverbeke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryse","family":"Assing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9967-3210","authenticated-orcid":false,"given":"Meriem","family":"Kessouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2305-5387","authenticated-orcid":false,"given":"Yves","family":"Brault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8845-4274","authenticated-orcid":false,"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"3304_CR1","unstructured":"European Medicines Agency. Inflectra (infliximab) european public assessment report product information 2013 [updated 12 May 2022. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/inflectra. Accessed 9 Jul 2025."},{"key":"3304_CR2","unstructured":"European Medicines Agency. Remsima (infliximab) european public assessment report product information 2013 [updated 17 May 2022. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remsima. Accessed 9 Jul 2025."},{"key":"3304_CR3","unstructured":"Celltrion Healthcare. Remsima\u00ae 2020 [Available from: https:\/\/www.celltrionhealthcare.com\/en-us\/products\/product\/?pkey=5. Accessed 9 Jul 2025."},{"key":"3304_CR4","unstructured":"GaBi Online (Generics and Biosimilars Initaitive). Biosimilars of infliximab 2015 [updated 27 November 2020. Available from: https:\/\/www.gabionline.net\/biosimilars\/general\/Biosimilars-of-infliximab. Accessed 9 Jul 2025."},{"key":"3304_CR5","unstructured":"PMLiVE. Remicade biosimilars hit European market Surrey, England: PMGroup; 2015 [Available from: https:\/\/www.pmlive.com\/pharma_news\/remicade_biosimilars_hit_european_market_662306. Accessed 9 Jul 2025."},{"issue":"10","key":"3304_CR6","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"3304_CR7","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3304_CR8","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/joim.12880","volume":"285","author":"GL Goll","year":"2019","unstructured":"Goll GL, Jorgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. J Intern Med. 2019;285(6):653\u201369.","journal-title":"J Intern Med"},{"issue":"5","key":"3304_CR9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s40259-020-00438-7","volume":"34","author":"KK Jorgensen","year":"2020","unstructured":"Jorgensen KK, Goll GL, Sexton J, Bolstad N, Olsen IC, Asak O, et al. Efficacy and safety of CT-P13 in inflammatory bowel disease after switching from originator infliximab: exploratory analyses from the NOR-SWITCH main and extension trials. BioDrugs. 2020;34(5):681\u201394.","journal-title":"BioDrugs"},{"issue":"10086","key":"3304_CR10","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK Jorgensen","year":"2017","unstructured":"Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304\u201316.","journal-title":"Lancet"},{"issue":"6","key":"3304_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40259-016-0202-5","volume":"30","author":"M Beck","year":"2016","unstructured":"Beck M, Michel B, Rybarczyk-Vigouret MC, Leveque D, Sordet C, Sibilia J, et al. Rheumatologists\u2019 perceptions of biosimilar medicines prescription: findings from a French web-based survey. BioDrugs. 2016;30(6):585\u201392.","journal-title":"BioDrugs"},{"issue":"4","key":"3304_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jbspin.2019.01.001","volume":"86","author":"L Frantzen","year":"2019","unstructured":"Frantzen L, Cohen JD, Trope S, Beck M, Munos A, Sittler MA, et al. Patients\u2019 information and perspectives on biosimilars in rheumatology: a French nation-wide survey. Joint Bone Spine. 2019;86(4):491\u20136.","journal-title":"Joint Bone Spine"},{"key":"3304_CR13","unstructured":"ClinicalTrials.gov. National observational study on the use of inflectra\u2122 an infliximab biosimilar in real life (ReFLECT) 2016 [updated 7 February 2022. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02925338. Accessed 9 Jul 2025."},{"issue":"10","key":"3304_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102483","volume":"48","author":"D Laharie","year":"2024","unstructured":"Laharie D, Bouhnik Y, Vuitton L, Biron A, Pierron G, Brault Y, et al. Real-world effectiveness and safety of CT-P13, an infliximab biosimilar, for inflammatory bowel diseases: a prospective national observational cohort study (ReFLECT study). Clin Res Hepatol Gastroenterol. 2024;48(10): 102483.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"6","key":"3304_CR15","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.semarthrit.2016.09.005","volume":"46","author":"K Aaltonen","year":"2017","unstructured":"Aaltonen K, Heinonen A, Joensuu J, Parmanne P, Karjalainen A, Varjolahti-Lehtinen T, et al. Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: a prospective cohort study. Semin Arthritis Rheum. 2017;46(6):732\u20139.","journal-title":"Semin Arthritis Rheum"},{"key":"3304_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151979","volume":"53","author":"A Egeberg","year":"2022","unstructured":"Egeberg A, Roseno NAL, Aagaard D, Lorup EH, Nielsen ML, Nymand L, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - a nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53: 151979.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"3304_CR17","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1136\/ard.2005.045062","volume":"65","author":"A Finckh","year":"2006","unstructured":"Finckh A, Simard JF, Gabay C, Guerne PA. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis. 2006;65(6):746\u201352.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3304_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105193","volume":"9","author":"A Fisher","year":"2014","unstructured":"Fisher A, Bassett K, Wright JM, Brookhart MA, Freeman H, Dormuth CR. Comparative persistence of the TNF antagonists in rheumatoid arthritis\u2013a population-based cohort study. PLoS ONE. 2014;9(8): e105193.","journal-title":"PLoS ONE"},{"issue":"2","key":"3304_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40744-019-0148-4","volume":"6","author":"T Hunter","year":"2019","unstructured":"Hunter T, Schroeder K, Sandoval D, Deodhar A. Persistence, discontinuation, and switching patterns of newly initiated TNF inhibitor therapy in ankylosing spondylitis patients in the United States. Rheumatol Ther. 2019;6(2):207\u201315.","journal-title":"Rheumatol Ther"},{"key":"3304_CR20","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/j.1749-6632.2009.04621.x","volume":"1173","author":"A Marchesoni","year":"2009","unstructured":"Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009;1173:837\u201346.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"3304_CR21","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/rheumatology\/kex457","volume":"57","author":"F Yahya","year":"2018","unstructured":"Yahya F, Gaffney K, Hamilton L, Lonsdale E, Leeder J, Brooksby A, et al. Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort. Rheumatology (Oxford). 2018;57(4):619\u201324.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"3304_CR22","doi-asserted-by":"publisher","first-page":"rkab026","DOI":"10.1093\/rap\/rkab026","volume":"5","author":"PC Taylor","year":"2021","unstructured":"Taylor PC, Christensen R, Moosavi S, Selema P, Guilatco R, Fowler H, et al. Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST). Rheumatol Adv Pract. 2021;5(2):rkab026.","journal-title":"Rheumatol Adv Pract"},{"issue":"5","key":"3304_CR23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.semarthrit.2017.10.002","volume":"47","author":"J Avouac","year":"2018","unstructured":"Avouac J, Molto A, Abitbol V, Etcheto A, Salcion A, Gutermann L, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: the experience of Cochin University Hospital, Paris. France Semin Arthritis Rheum. 2018;47(5):741\u20138.","journal-title":"France Semin Arthritis Rheum"},{"issue":"9","key":"3304_CR24","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1093\/rheumatology\/keab933","volume":"61","author":"D Di Giuseppe","year":"2022","unstructured":"Di Giuseppe D, Lindstrom U, Bower H, Delcoigne B, Frisell T, Chatzidionysiou K, et al. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden. Rheumatology (Oxford). 2022;61(9):3596\u2013605.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"3304_CR25","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","volume":"76","author":"B Glintborg","year":"2017","unstructured":"Glintborg B, Sorensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76(8):1426\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3304_CR26","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/1756-185X.13512","volume":"22","author":"Z Layegh","year":"2019","unstructured":"Layegh Z, Ruwaard J, Hebing RCF, I\u2019Ami MJ, Weele WVD, Nurmohamed MT, et al. Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice. Int J Rheum Dis. 2019;22(5):869\u201373.","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"3304_CR27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jbspin.2017.10.003","volume":"85","author":"M Scherlinger","year":"2018","unstructured":"Scherlinger M, Germain V, Labadie C, Barnetche T, Truchetet ME, Bannwarth B, et al. Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance. Joint Bone Spine. 2018;85(5):561\u20137.","journal-title":"Joint Bone Spine"},{"issue":"4","key":"3304_CR28","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/mr\/roab068","volume":"32","author":"T Takeuchi","year":"2022","unstructured":"Takeuchi T, Nishikawa K, Yamada F, Ohshima S, Inoue M, Yoshioka Y, et al. Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naive to or switched from biologics. Mod Rheumatol. 2022;32(4):718\u201327.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"3304_CR29","doi-asserted-by":"publisher","first-page":"rkad031","DOI":"10.1093\/rap\/rkad031","volume":"7","author":"B Fautrel","year":"2023","unstructured":"Fautrel B, Bouhnik Y, Dieude P, Richette P, Dougados M, Freudensprung U, et al. Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study. Rheumatol Adv Pract. 2023;7(2):rkad031.","journal-title":"Rheumatol Adv Pract"},{"issue":"6","key":"3304_CR30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s40261-020-00907-5","volume":"40","author":"TH Kim","year":"2020","unstructured":"Kim TH, Lee SS, Park W, Song YW, Suh CH, Kim S, et al. A 5-year retrospective analysis of drug survival, safety, and effectiveness of the infliximab biosimilar CT-P13 in patients with rheumatoid arthritis and ankylosing spondylitis. Clin Drug Investig. 2020;40(6):541\u201353.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"3304_CR31","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/1756-185X.13305","volume":"21","author":"SC Bae","year":"2018","unstructured":"Bae SC, Lee YH. Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials. Int J Rheum Dis. 2018;21(5):922\u20139.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"3304_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/1744666X.2020.1858803","volume":"17","author":"R Caporali","year":"2021","unstructured":"Caporali R, Allanore Y, Alten R, Combe B, Durez P, Iannone F, et al. Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. Expert Rev Clin Immunol. 2021;17(1):85\u201399.","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"3304_CR33","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1007\/s12325-021-01834-3","volume":"38","author":"JH Cheon","year":"2021","unstructured":"Cheon JH, Nah S, Kang HW, Lim YJ, Lee SH, Lee SJ, et al. Infliximab biosimilar CT-P13 observational studies for rheumatoid arthritis, inflammatory bowel diseases, and ankylosing spondylitis: pooled analysis of long-term safety and effectiveness. Adv Ther. 2021;38(8):4366\u201387.","journal-title":"Adv Ther"},{"issue":"4","key":"3304_CR34","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40259-020-00421-2","volume":"34","author":"SJ Lee","year":"2020","unstructured":"Lee SJ, Baek K, Lee S, Lee YJ, Park JE, Lee SG. Post-marketing pooled safety analysis for CT-P13 treatment of patients with immune-mediated inflammatory diseases in observational cohort studies. BioDrugs. 2020;34(4):513\u201328.","journal-title":"BioDrugs"},{"key":"3304_CR35","unstructured":"European Medicines Agency. Remicade (infliximab) european public assessment report product information 1999 [updated 26 April 2022. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remicade. Accessed 9 Jul 2025."},{"issue":"8","key":"3304_CR36","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1093\/rheumatology\/keac689","volume":"62","author":"A Constantin","year":"2023","unstructured":"Constantin A, Caporali R, Edwards CJ, Fonseca JE, Iannone F, Keystone E, et al. Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial. Rheumatology (Oxford). 2023;62(8):2838\u201344.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"3304_CR37","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/rheumatology\/keaa580","volume":"60","author":"R Westhovens","year":"2021","unstructured":"Westhovens R, Wiland P, Zawadzki M, Ivanova D, Kasay AB, El-Khouri EC, et al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I\/III trial. Rheumatology (Oxford). 2021;60(5):2277\u201387.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03304-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03304-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03304-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T04:27:59Z","timestamp":1757305679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03304-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3304"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03304-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hubert Marotte has received consulting fees and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie, Biogen Bristol-Myers Squibb, Celltrion, Eli Lilly, Fresenius Kabi, Galapagos, Janssen, Medac, NORDIC Pharma, Novartis, Pfizer, and UCB. Alain Cantagrel has received consulting fees from Eli Lilly and Janssen and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Medac, Novartis, Pfizer, and UCB. Fabienne Coury has received research grants paid to her institution (Hospices Civils de Lyon, Lyon Recherche Clinique) from Biogen, Chugai, Novartis, and UCB; consulting fees from Amgen, Chugai, Janssen, Eli Lilly, and UCB; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie and Eli Lilly; and support for travel from AbbVie and Eli Lilly. Thierry Schaeverbeke: has received research support from AbbVie, Abivax, Biogen, Eli Lilly, MSD, Novartis, Pfizer, and Sandoz; consulting fees for advisory boards from AbbVie, Bristol-Myers Squibb, Eli Lilly, Novartis, Pfizer, and Sanofi; and payment or honoraria for educational events from AbbVie, Biogen, Bristol-Myers Squibb, Eli Lilly, Galapagos, Janssen, Nordic Pharma, Novartis, Pfizer, and Viatris. Bruno Fautrel has received consulting fees and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Chugai, Eli Lilly, Fresenius Kabi, Galapagos, Janssen, Medac, MSD, NORDIC Pharma, Novartis, OWKIN, Pfizer, Roche, Sandoz, Sanofi-Genzyme, SOBI, UCB, and Viatris. Maryse Assing, Yves Brault, and Meriem Kessouri are employees of and hold stock or stock options in Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Patients (or their legal representatives) completed a written informed consent form and authorized access to their clinical data and medical records before enrollment. This observational study was registered with the National Commission on Data Processing and Freedoms. This study was conducted in accordance with the Declaration of Helsinki and was approved by the French Advisory Committee on the Treatment of Information in Health Research (CCTIR number 16-207; 23\/03\/2016) and by the French Data Protection Authority (CNIL) (approval ref: MMS\/VCS\/ARS169124\/request number: 916228; 30\/09\/2016)), which were the requirements at the time this study was conducted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}